WO2007005940A3 - Combinaisons d'eszopiclone et de didesmethylsibutramine, methodes de traitement de la menopause, de l'humeur, de l'anxiete et des troubles de la connaissance - Google Patents

Combinaisons d'eszopiclone et de didesmethylsibutramine, methodes de traitement de la menopause, de l'humeur, de l'anxiete et des troubles de la connaissance Download PDF

Info

Publication number
WO2007005940A3
WO2007005940A3 PCT/US2006/026146 US2006026146W WO2007005940A3 WO 2007005940 A3 WO2007005940 A3 WO 2007005940A3 US 2006026146 W US2006026146 W US 2006026146W WO 2007005940 A3 WO2007005940 A3 WO 2007005940A3
Authority
WO
WIPO (PCT)
Prior art keywords
didesmethylsibutramine
menopause
anxiety
mood
eszopiclone
Prior art date
Application number
PCT/US2006/026146
Other languages
English (en)
Other versions
WO2007005940A2 (fr
Inventor
Judy Caron
Thomas Wessel
Karim Lalji
Mark A Varney
Original Assignee
Sepracor Inc
Judy Caron
Thomas Wessel
Karim Lalji
Mark A Varney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc, Judy Caron, Thomas Wessel, Karim Lalji, Mark A Varney filed Critical Sepracor Inc
Publication of WO2007005940A2 publication Critical patent/WO2007005940A2/fr
Publication of WO2007005940A3 publication Critical patent/WO2007005940A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un aspect de la présente invention concerne des compositions pharmaceutiques contenant au moins deux agents actifs qui, lorsqu'ils sont pris ensemble, peuvent être utilisés pour traiter, par exemple, la ménopause, les troubles de l'humeur, les troubles anxieux ou les troubles de la connaissance. Le premier constituant de la composition pharmaceutique est un eszopiclone sédatif. Le deuxième constituant de la composition pharmaceutique est la didesméthylsibutramine ou (S)-didesméthylsibutramine. Cette invention porte également sur une méthode de traitement de la ménopause, de la périménopause, des troubles de l'humeur, des troubles anxieux et des troubles de la connaissance.
PCT/US2006/026146 2005-07-06 2006-07-05 Combinaisons d'eszopiclone et de didesmethylsibutramine, methodes de traitement de la menopause, de l'humeur, de l'anxiete et des troubles de la connaissance WO2007005940A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69688005P 2005-07-06 2005-07-06
US60/696,880 2005-07-06

Publications (2)

Publication Number Publication Date
WO2007005940A2 WO2007005940A2 (fr) 2007-01-11
WO2007005940A3 true WO2007005940A3 (fr) 2007-06-28

Family

ID=37605184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/026146 WO2007005940A2 (fr) 2005-07-06 2006-07-05 Combinaisons d'eszopiclone et de didesmethylsibutramine, methodes de traitement de la menopause, de l'humeur, de l'anxiete et des troubles de la connaissance

Country Status (1)

Country Link
WO (1) WO2007005940A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329950B2 (en) 2005-07-06 2012-12-11 Sunovion Pharmaceuticals Inc. Process for preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1Napthalenamine

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004305563C1 (en) * 2003-12-11 2011-07-07 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
AU2005215376B2 (en) 2004-02-18 2011-01-20 Sunovion Pharmaceuticals Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US9616123B1 (en) * 2012-03-05 2017-04-11 Robert L. Knobler Method and compound for treatment of menopausal symptoms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806570A (en) * 1981-04-06 1989-02-21 The Boots Company Plc Therapeutic agents
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806570A (en) * 1981-04-06 1989-02-21 The Boots Company Plc Therapeutic agents
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329950B2 (en) 2005-07-06 2012-12-11 Sunovion Pharmaceuticals Inc. Process for preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1Napthalenamine

Also Published As

Publication number Publication date
WO2007005940A2 (fr) 2007-01-11

Similar Documents

Publication Publication Date Title
WO2007005961A3 (fr) Combinaisons d'un eszopiclone et d'un o-desmethylvenlafaxine, et methodes de traitement de la menopause et de l'humeur, de l'anxiete et des troubles cognitifs
WO2007006003A3 (fr) Combinaisons d'eszopiclone et de trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphtalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphtalenamine, et methodes de traitement de la menopause et des troubles de l'humeur, de l'anxiete et troubles cognitifs
WO2007005962A3 (fr) Combinaisons d'un eszopiclone et d'un antidepresseur, et methodes de traitement de la menopause et de l'humeur, de l'anxiete et des troubles cognitifs
WO2007005940A3 (fr) Combinaisons d'eszopiclone et de didesmethylsibutramine, methodes de traitement de la menopause, de l'humeur, de l'anxiete et des troubles de la connaissance
WO2006024018A3 (fr) Methodes et compositions pour le traitement de la douleur nociceptive
WO2006091459A3 (fr) Compositions et methodes permettant de traiter la permeabilite vasculaire
WO2006003388A3 (fr) Compositions et procedes pour le traitement de troubles inflammatoires
WO2006105516A3 (fr) Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2008089310A3 (fr) Méthodes et compositions utilisées dans le traitement de troubles corporels
WO2007098089A3 (fr) Traitment de maladies hyperprolifératives avec du n-oxide de méthotrexate et des analogues correspondants
WO2004078116A3 (fr) Inhibiteurs de la p 38 et leurs procedes d'utilisation
BRPI0507250A (pt) combinações para tratar desordens do snc
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2007087250A3 (fr) Inhibiteurs tricycliques de la 5-lipoxygenase
WO2006124748A3 (fr) Composes polycycliques et procedes pour les utiliser
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
WO2005118511A3 (fr) Composes, compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
WO2006055871A3 (fr) Traitement de la sclerose en plaques
WO2006034491A3 (fr) Composes a base de quinoleine et de quinazoline a substitution phenylique pour le traitement du diabete
WO2006009975A3 (fr) Utilisation d'histamine et de composes associes pour traiter des troubles de la fonction musculaire
WO2007112121A3 (fr) Composés à base de tétracyline et procédés de traitement
WO2006109301A3 (fr) Molecules et procedes d'utilisation correspondants pour le traitement d'affections associees a mcp-1/ccr2
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06786335

Country of ref document: EP

Kind code of ref document: A2